Fortress Biotech has launched Tamid Bio, a subsidiary dedicated to the development of adeno-associated virus (AAV) gene therapies in orphan diseases with unmet medical needs. As part of its formation, Tamid has entered into three exclusive licensing agreements with the University of North Carolina at Chapel Hill for three preclinical AAV gene therapies, developed in the lab of Matthew Hirsch, assistant professor, ophthalmology, at the UNC Gene Therapy Center. Tamid’s lead program, Tamid-001, ...